From Gut to Bloodstream
When you swallow a tablet, the drug must dissolve, cross the intestinal membrane, and survive first-pass metabolism before reaching systemic circulation. The absorption rate constant ka captures this complex process as a single first-order parameter. Faster absorption (higher ka) means a sharper, earlier peak — critical for analgesics where rapid pain relief matters, but potentially dangerous for drugs with narrow therapeutic windows.
The Bateman Curve
The plasma concentration-time profile after oral dosing follows the Bateman equation — a difference of two exponentials. The ascending limb reflects net absorption exceeding elimination; the descending limb reflects the opposite. The peak (Cmax) occurs at tmax, the moment absorption and elimination rates are exactly equal. This curve is the foundation of therapeutic drug monitoring.
Volume of Distribution
Vd is a proportionality constant linking the amount of drug in the body to its plasma concentration. A drug confined to plasma (like warfarin, Vd ~ 8 L) has a small Vd; one that accumulates in fat or muscle (like chloroquine, Vd ~ 15,000 L) has an enormous Vd. This parameter directly affects peak concentration: doubling Vd halves Cmax for the same dose.
Clinical Implications
Understanding absorption kinetics guides dosing decisions. Extended-release formulations deliberately lower ka to flatten the curve, keeping drug levels within the therapeutic window for longer. Conversely, sublingual or inhaled routes bypass the gut entirely, achieving near-instantaneous absorption. These simulations help visualize why the same drug molecule can behave so differently depending on how it enters the body.